Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data

A week after nabbing a priority review, Alnylam has released pivotal data for their latest late-stage experimental drug — setting the stage for the RNA-targeting biotech to potentially win their 3rd FDA approval in as many years.